Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.

The new drug, simply called the Wegovy pill, marks a turning point in the modern weight-loss revolution. Until now, every ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

The average weight increase after 52 weeks for Wegovy patients was 2 pounds, whereas Zepbound patients gained 11 pounds. Eli ...

Quick Read Novo Nordisk (NVO) received FDA approval for the first oral Wegovy pill. The once-daily tablet delivered 16.6% ...

Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. Novo has a new ...

A DAILY weight loss pill that helped patients shed up to 20 per cent of their body weight in trials has been given the green ...

The competitive landscape for obesity medications is undergoing a significant shift. Eli Lilly now confronts intensified ...

The pharmaceutical sector's most intense rivalry is escalating. Eli Lilly has unveiled pivotal Phase 3 trial results for its ...

Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.